Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Capexion 1mg capsules
0802020T0BHABAB
|
Capexion | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Capexion 5mg capsules
0802020T0BHACAA
|
Capexion | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Caprelsa 100mg tablets
0801050BGBBAAAA
|
Caprelsa | Vandetanib | Malignant Disease and Immunosuppression | No data available |
|
Caprelsa 300mg tablets
0801050BGBBABAB
|
Caprelsa | Vandetanib | Malignant Disease and Immunosuppression | No data available |
|
Capsorin 100mg/ml oral solution
0802020G0BGADAG
|
Capsorin | Ciclosporin | Malignant Disease and Immunosuppression | No data available |
|
Carac 0.5% cream
0801030H0BFAAAV
|
Carac | Fluorouracil (Antimetabolites) | Malignant Disease and Immunosuppression | No data available |
|
Carboplatin 150mg/15ml solution for infusion vials
0801050F0AAAEAE
|
Carboplatin | Carboplatin | Malignant Disease and Immunosuppression | No data available |
|
Carboplatin 450mg/45ml solution for infusion vials
0801050F0AAAFAF
|
Carboplatin | Carboplatin | Malignant Disease and Immunosuppression | No data available |
|
Carboplatin 50mg/5ml solution for infusion vials
0801050F0AAADAD
|
Carboplatin | Carboplatin | Malignant Disease and Immunosuppression | No data available |
|
Carboplatin 600mg/60ml solution for infusion vials
0801050F0AAAGAG
|
Carboplatin | Carboplatin | Malignant Disease and Immunosuppression | No data available |
|
Cardioxane 500mg powder for solution for infusion vials
0801000Y0BBAAAA
|
Cardioxane | Dexrazoxane | Malignant Disease and Immunosuppression | No data available |
|
Carmustine 100mg inf vials
0801010D0AAAAAA
|
Carmustine | Carmustine | Malignant Disease and Immunosuppression | No data available |
|
Carmustine 7.7mg implant
0801010D0AAABAB
|
Carmustine | Carmustine | Malignant Disease and Immunosuppression | No data available |
|
Catumaxomab 10micrograms/0.1ml inf pre-filled syringes
0801050BFAAABAB
|
Catumaxomab | Catumaxomab | Malignant Disease and Immunosuppression | No data available |
|
Catumaxomab 50micrograms/0.5ml inf pre-filled syringes
0801050BFAAAAAA
|
Catumaxomab | Catumaxomab | Malignant Disease and Immunosuppression | No data available |
|
CeeNU 100mg capsules
0801010Q0BBADAD
|
CeeNU | Lomustine | Malignant Disease and Immunosuppression | No data available |
|
CeeNU 10mg capsules
0801010Q0BBACAA
|
CeeNU | Lomustine | Malignant Disease and Immunosuppression | No data available |
|
CellCept 500mg powder for solution for infusion vials
0802010M0BBADAH
|
CellCept | Mycophenolate mofetil | Malignant Disease and Immunosuppression | No data available |
|
Ceplene 0.5mg/0.5ml solution for injection vials
0802040ABBBAAAA
|
Ceplene | Histamine dihydrocloride | Malignant Disease and Immunosuppression | No data available |
|
Certican 0.25mg tablets
0801050AXBDAAAD
|
Certican | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Certican 0.5mg tablets
0801050AXBDACAF
|
Certican | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Certican 0.75mg tablets
0801050AXBDABAE
|
Certican | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Cetuximab 100mg/20ml solution for infusion vials
0801050AGAAABAB
|
Cetuximab | Cetuximab | Malignant Disease and Immunosuppression | No data available |
|
Cetuximab 100mg/50ml solution for infusion vials
0801050AGAAAAAA
|
Cetuximab | Cetuximab | Malignant Disease and Immunosuppression | No data available |
|
Cetuximab 500mg/100ml solution for infusion vials
0801050AGAAACAC
|
Cetuximab | Cetuximab | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.